VistaGen Therapeutics, Inc. (VTGN) Financial Statements (2024 and earlier)

Company Profile

Business Address 343 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. NV
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
3/31/2023
12/31/2022
MRQ
3/31/2022
3/31/2021
3/31/2020
3/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments16,63825,03768,135103,1081,35513,100
Cash and cash equivalents16,63825,03768,135103,1081,35513,100
Receivables    41 300
Prepaid expense    122 96
Capitalized contract cost  67    
Deferred costs6767117134  
Other undisclosed current assets8038862,746713225155
Total current assets:17,50726,05870,998104,1181,58013,651
Noncurrent Assets
Operating lease, right-of-use asset2,2602,3642,6623,2203,580
Property, plant and equipment507541414367210313
Capitalized contract cost, net  234    
Deposits noncurrent assets101101101   
Deferred costs218234146234  
Other undisclosed noncurrent assets49617732234340348
Total noncurrent assets:3,5823,6513,6454,1644,192361
TOTAL ASSETS:21,08929,70974,643108,2815,77214,012
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,2612,6844,1542,4012,3982,741
Employee-related liabilities66   
Accounts payable2,4731,5992,7598381,8371,055
Accrued liabilities7871,0851,3291,5635621,686
Deferred revenue7147121,2441,420 
Debt22 36060
Other undisclosed current liabilities591890367365313 
Total current liabilities:4,5674,2875,7654,1892,7712,801
Noncurrent Liabilities
Long-term debt and lease obligation782,6053,3513,7196
Capital lease obligations6
Finance lease, liability78  3
Liabilities, other than long-term debt4,4344,7391,5582,490 381
Deferred revenue2,3152,4921,5582,490 
Deferred rent credit      381
Operating lease, liability2,1202,2472,6053,3513,716
Other undisclosed noncurrent liabilities    6,2731,2963,748
Total noncurrent liabilities:4,4424,7474,16312,1148,7304,136
Total liabilities:9,0099,0349,92816,30311,5026,937
Equity
Equity, attributable to parent, including:12,08020,67564,71591,979(5,729)7,075
Common stock72072071814943
Treasury stock, value(3,968)(3,968)(3,968)(3,968)(3,968)(3,968)
Additional paid in capital342,893339,060336,081315,603200,093192,130
Accumulated deficit(326,852)(314,625)(267,604)(219,842)(201,907)(181,133)
Other undisclosed equity, attributable to parent    444
Total equity:12,08020,67564,71591,979(5,729)7,075
TOTAL LIABILITIES AND EQUITY:21,08929,70974,643108,2815,77214,012

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
3/31/2023
12/31/2022
TTM
3/31/2022
3/31/2021
3/31/2020
3/31/2019
Revenues(227)7721,1091,090  
Gross profit:(227)7721,1091,090  
Operating expenses(59,041)(83,152)(48,888)(19,023)(20,802)(24,556)
Other undisclosed operating income (loss)(0)(713)(0)   
Operating loss:(59,268)(83,093)(47,779)(17,934)(20,802)(24,556)
Interest and debt expense      (31)
Other undisclosed income from continuing operations before equity method investments, income taxes  6    
Loss from continuing operations before equity method investments, income taxes:(59,268)(83,087)(47,779)(17,934)(20,802)(24,587)
Other undisclosed income from continuing operations before income taxes263420230 
Loss from continuing operations before income taxes:(59,242)(83,054)(47,759)(17,932)(20,771)(24,587)
Income tax expense(6)(6)(3)(3)(3)(3)
Loss from continuing operations:(59,248)(83,060)(47,762)(17,934)(20,774)(24,590)
Loss before gain (loss) on sale of properties:(73,299)(47,762)(17,934)(20,774)(24,590)
Net loss attributable to parent:(59,248)(83,060)(47,762)(17,934)(20,774)(24,590)
Preferred stock dividends and other adjustments  92(945)   
Other undisclosed net loss available to common stockholders, basic    (24,386)(1,264)(1,140)
Net loss available to common stockholders, diluted:(59,248)(82,968)(48,708)(42,320)(22,038)(25,730)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
3/31/2023
12/31/2022
TTM
3/31/2022
3/31/2021
3/31/2020
3/31/2019
Net loss:(59,248)(83,060)(47,762)(17,934)(20,774)(24,590)
Comprehensive loss, net of tax, attributable to parent:(59,248)(83,060)(47,762)(17,934)(20,774)(24,590)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: